Dallan Murray News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dallan murray. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dallan Murray Today - Breaking & Trending Today

Bellevue Group AG Sells 4,466 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bellevue Group AG trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.8% during the fourth quarter, Holdings Channel reports. The fund owned 237,286 shares of the biotechnology company’s stock after selling 4,466 shares during the quarter. Bellevue Group AG’s holdings in Sarepta Therapeutics were worth $22,881,000 as of its most recent […] ....

Third Bancorp , Montaga Associates Inc , Holdings Channel , Fifth Third Bancorp , Bellevue Group , Principal Securities Inc , Partners Investment Advisory , Sarepta Therapeutics Inc , Cantor Fitzgerald , Sarepta Therapeutics , Free Report , Street Partners Investment Advisory , Get Free Report , Dallan Murray , Visit Holdingschannel , Sarepta Therapeutics Daily ,

Bellevue Group AG Lowers Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bellevue Group AG trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,286 shares of the biotechnology company’s stock after selling 4,466 shares during the […] ....

Partners Investment Advisory , Montaga Associates Inc , Principal Securities Inc , Third Bancorp , Cantor Fitzgerald , Bellevue Group , Exchange Commission , Sarepta Therapeutics Inc , Fifth Third Bancorp , Sarepta Therapeutics , Free Report , Street Partners Investment Advisory , Dallan Murray , Therapeutics Trading Down , Get Free Report , Sarepta Therapeutics Daily ,

Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sector perform” rating reissued by equities researchers at Royal Bank of Canada in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $142.00 price target on the biotechnology company’s stock, down from their prior price target of $157.00. Royal Bank of […] ....

Bilal Arif , Securities Exchange Commission , Royal Bank , Principal Securities Inc , Jpmorgan Chase Co , Mather Group , Partners Investment Advisory , Sarepta Therapeutics Inc , Riggs Asset Managment Co , Montaga Associates Inc , Sarepta Therapeutics , Get Free Report , Dallan Murray , Exchange Commission , Asset Managment , Cary Street Partners Investment Advisory , Street Partners Investment Advisory , Sarepta Therapeutics Daily ,